1-12 of 12
Rami S. Komrokji
Close
Sort by
Journal Articles

Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis

Clinical Trials & Observations
Aaron T. Gerds, Claire N. Harrison, Jean-Jacques Kiladjian, Ruben Mesa, Alessandro Maria Vannucchi, Rami S Komrokji, Prithviraj Bose, Marina Kremyanskaya, Adam Mead, Jason Gotlib, Shelonitda Rose, Fabian Sanabria, Niloufar Marsousi, Ana Carolina Giuseppi, MD, Huijing Jiang, Jeanne M Palmer, Kelly McCaul, Vincent Ribrag, Francesco Passamonti
Journal: Blood Advances
Blood Adv bloodadvances.2024012939.
https://doi.org/10.1182/bloodadvances.2024012939
Published: 2024
Includes: Supplemental data
Journal Articles

Telomerase-targeted therapies in myeloid malignancies

Julian A. Waksal, Claudia Bruedigam, Rami S. Komrokji, Catriona H. M. Jamieson, John O. Mascarenhas
Journal: Blood Advances
Blood Adv (2023) 7 (16): 4302–4314.
https://doi.org/10.1182/bloodadvances.2023009903
Published: 2023
Journal Articles

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes

Clinical Trials & Observations
Rami S. Komrokji, Luis E. Aguirre, Najla H. Al Ali, Onyee Chan, Zhuoer Xie, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman
Journal: Blood Advances
Blood Adv (2023) 7 (14): 3677–3679.
https://doi.org/10.1182/bloodadvances.2023009781
Published: 2023
Journal Articles

An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS

Clinical Trials & Observations
Maximilian Stahl, Omar Abdel-Wahab, Andrew H. Wei, Michael R. Savona, Mina L. Xu, Zhuoer Xie, Justin Taylor, Daniel Starczynowski, Guillermo F. Sanz, David A. Sallman, Valeria Santini, Gail J. Roboz, Mrinal M. Patnaik, Eric Padron, Olatoyosi Odenike, Aziz Nazha, Stephen D. Nimer, Ravindra Majeti, Richard F. Little, Steven Gore, Alan F. List, Vijay Kutchroo, Rami S. Komrokji, Tae Kon Kim, Nina Kim, Christopher S. Hourigan, Robert P. Hasserjian, Stephanie Halene, Elizabeth A. Griffiths, Peter L. Greenberg, Maria Figueroa, Pierre Fenaux, Fabio Efficace, Amy E. DeZern, Matteo G. Della Porta, Naval G. Daver, Jane E. Churpek, Hetty E. Carraway, Andrew M. Brunner, Uma Borate, John M. Bennett, Rafael Bejar, Jacqueline Boultwood, Sanam Loghavi, Jan Philipp Bewersdorf, Uwe Platzbecker, David P. Steensma, Mikkael A. Sekeres, Rena J. Buckstein, Amer M. Zeidan
Journal: Blood Advances
Blood Adv (2023) 7 (12): 2709–2714.
https://doi.org/10.1182/bloodadvances.2022008747
Published: 2023
Journal Articles

A geno-clinical decision model for the diagnosis of myelodysplastic syndromes

Clinical Trials & Observations
Nathan Radakovich, Manja Meggendorfer, Luca Malcovati, C. Beau Hilton, Mikkael A. Sekeres, Jacob Shreve, Yazan Rouphail, Wencke Walter, Stephan Hutter, Anna Galli, Sara Pozzi, Chiara Elena, Eric Padron, Michael R. Savona, Aaron T. Gerds, Sudipto Mukherjee, Yasunobu Nagata, Rami S. Komrokji, Babal K. Jha, Claudia Haferlach, Jaroslaw P. Maciejewski, Torsten Haferlach, Aziz Nazha
Journal: Blood Advances
Blood Adv (2021) 5 (21): 4361–4369.
https://doi.org/10.1182/bloodadvances.2021004755
Published: 2021
Includes: Supplemental data
Journal Articles

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes

Clinical Trials & Observations
Anthony M. Hunter, Rami S. Komrokji, Seongseok Yun, Najla Al Ali, Onyee Chan, Jinming Song, Mohammad Hussaini, Chetasi Talati, Kendra L. Sweet, Jeffrey E. Lancet, Eric Padron, Alan F. List, David A. Sallman
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1017–1028.
https://doi.org/10.1182/bloodadvances.2020003508
Published: 2021
Includes: Supplemental data
Journal Articles

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Clinical Trials & Observations
Brian J. Ball, Christopher A. Famulare, Eytan M. Stein, Martin S. Tallman, Andriy Derkach, Mikhail Roshal, Saar I. Gill, Benjamin M. Manning, Jamie Koprivnikar, James McCloskey, Rebecca Testi, Thomas Prebet, Najla H. Al Ali, Eric Padron, David A. Sallman, Rami S. Komrokji, Aaron D. Goldberg
Journal: Blood Advances
Blood Adv (2020) 4 (13): 2866–2870.
https://doi.org/10.1182/bloodadvances.2020001482
Published: 2020
Includes: Supplemental data
Journal Articles

A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)

Clinical Trials & Observations
Jeffrey E. Lancet, Anna B. Moseley, Steven E. Coutre, Daniel J. DeAngelo, Megan Othus, Martin S. Tallman, Mark R. Litzow, Rami S. Komrokji, Harry P. Erba, Frederick R. Appelbaum
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1683–1689.
https://doi.org/10.1182/bloodadvances.2019001278
Published: 2020
Journal Articles

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Clinical Trials & Observations
Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Koji Sasaki, Keyur Patel, Irene Ganan-Gomez, Elias Jabbour, Tapan Kadia, Farhad Ravandi, Courtney DiNardo, Gautham Borthakur, Koichi Takahashi, Marina Konopleva, Rami S. Komrokji, Amy DeZern, Teodora Kuzmanovic, Jaroslaw Maciejewski, Sherry Pierce, Simona Colla, Mikkael A. Sekeres, Hagop Kantarjian, Carlos Bueso-Ramos, Guillermo Garcia-Manero
Journal: Blood Advances
Blood Adv (2019) 3 (6): 922–933.
https://doi.org/10.1182/bloodadvances.2018026989
Published: 2019
Includes: Supplemental data
Journal Articles

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia

Clinical Trials & Observations
Brian Ball, Rami S. Komrokji, Lionel Adès, Mikkael A. Sekeres, Amy E. DeZern, Lisa Pleyer, Norbert Vey, Antonio Almeida, Ulrich Germing, Thomas Cluzeau, Uwe Platzbecker, Steven D. Gore, Pierre Fenaux, Thomas Prebet
Journal: Blood Advances
Blood Adv (2018) 2 (16): 2063–2071.
https://doi.org/10.1182/bloodadvances.2018015529
Published: 2018
Includes: Supplemental data
Journal Articles

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort

Clinical Trials & Observations
Maximilian Stahl, Michelle DeVeaux, Theo de Witte, Judith Neukirchen, Mikkael A. Sekeres, Andrew M. Brunner, Gail J. Roboz, David P. Steensma, Vijaya R. Bhatt, Uwe Platzbecker, Thomas Cluzeau, Pedro H. Prata, Raphaël Itzykson, Pierre Fenaux, Amir T. Fathi, Alexandra Smith, Ulrich Germing, Ellen K. Ritchie, Vivek Verma, Aziz Nazha, Jaroslaw P. Maciejewski, Nikolai A. Podoltsev, Thomas Prebet, Valeria Santini, Steven D. Gore, Rami S. Komrokji, Amer M. Zeidan
Journal: Blood Advances
Blood Adv (2018) 2 (14): 1765–1772.
https://doi.org/10.1182/bloodadvances.2018019414
Published: 2018
Journal Articles

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

Clinical Trials & Observations
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, Raphael Itzykson, Ellen K. Ritchie, Mikkael A. Sekeres, John D. Barnard, Nikolai A. Podoltsev, Andrew M. Brunner, Rami S. Komrokji, Vijaya R. Bhatt, Aref Al-Kali, Thomas Cluzeau, Valeria Santini, Amir T. Fathi, Gail J. Roboz, Pierre Fenaux, Mark R. Litzow, Sarah Perreault, Tae Kon Kim, Thomas Prebet, Norbert Vey, Vivek Verma, Ulrich Germing, Juan Miguel Bergua, Josefina Serrano, Steven D. Gore, Amer M. Zeidan
Journal: Blood Advances
Blood Adv (2018) 2 (8): 923–932.
https://doi.org/10.1182/bloodadvances.2018016121
Published: 2018
Includes: Supplemental data